Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
08 Agosto 2024 - 3:30PM
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company
reimagining therapeutic delivery, today announced it will report
financial results and provide a corporate update for the second
quarter ended June 30, 2024. Company management will host a webcast
and conference call on Monday, August 12, 2024, after the close of
financial markets.
Conference Call and Webcast Information |
Date: |
Monday, August 12, 2024 |
Time: |
4:30 PM Eastern time / 1:30 PM
Pacific time |
Conference
Call: |
Domestic 1-877-423-9813
International 1-201-689-8573 Conference ID 13747616Call me for
instant telephone access |
Live
Webcast: |
https://investors.bioratherapeutics.com/events-presentations |
|
|
A replay will remain available for 60 days on the company’s
website.
About Biora TherapeuticsBiora Therapeutics is a
clinical-stage biotech developing two smart pill-based therapeutics
platforms: the NaviCap™ platform for colon-targeted treatment of
IBD, designed to improve patient outcomes through treatment at the
site of disease in the gastrointestinal tract, and the BioJet™
platform for oral delivery of large molecules, designed to replace
injection with needle-free delivery for better management of
chronic diseases.
For more information, visit bioratherapeutics.com or follow the
company on LinkedIn or X.
Safe Harbor Statement or Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, which
statements are subject to substantial risks and uncertainties and
are based on estimates and assumptions. All statements, other than
statements of historical facts included in this press release,
including statements concerning the progress and future
expectations and goals of our research and development, preclinical
and clinical trial activities, including those involving BT-600 and
our NaviCap platform and model projections, and partnering and
collaboration efforts with third parties, are forward-looking
statements. In some cases, you can identify forward-looking
statements by terms such as “envision,” “may,” “might,” “will,”
“objective,” “intend,” “should,” “could,” “can,” “would,” “expect,”
“anticipate,” “forward,” “believe,” “design,” “estimate,”
“predict,” “projects,” “projecting,” “potential,” “plan,”
“goal(s),” “target,” or the negative of these terms, and similar
expressions intended to identify forward-looking statements. These
statements reflect our plans, estimates, and expectations, as of
the date of this press release. These statements involve known and
unknown risks, uncertainties and other factors that could cause our
actual results to differ materially from the forward-looking
statements expressed or implied in this press release. Such risks,
uncertainties, and other factors include, among others, our ability
to innovate in the field of therapeutics, our ability to make
future FDA filings and initiate and execute clinical trials on
expected timelines or at all, our ability to obtain and maintain
regulatory approval or clearance of our products on expected
timelines or at all, our plans to research, develop, and
commercialize new products, the unpredictable relationship between
preclinical study results and clinical study results, our
expectations regarding allowed patents or intended grants to result
in issued or granted patents, our expectations regarding
opportunities with current or future pharmaceutical collaborators
or partners, our ability to raise sufficient capital to achieve our
business objectives, our ability to maintain our listing on the
Nasdaq Global Market, and those risks described in “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition
and Results of Operations” in our Annual Report on Form 10-K for
the year ended December 31, 2023 filed with the Securities and
Exchange Commission (SEC) and other subsequent documents, including
Quarterly Reports on Form 10-Q, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update
any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
law.
Investor ContactChuck PadalaManaging Director,
LifeSci AdvisorsIR@bioratherapeutics.com (646) 627-8390
Media ContactLiz RobinsonCG
Lifelrobinson@cglife.com
Biora Therapeutics (NASDAQ:BIOR)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Biora Therapeutics (NASDAQ:BIOR)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024